000045103 000__ 00930cam\a22003375i\4500
000045103 001__ 45103
000045103 003__ SzGeWIPO
000045103 005__ 20240708150059.0
000045103 006__ m\\\\eo\\d\\\\\\\\
000045103 007__ cr bn |||m|||a
000045103 008__ 220304s2021\\\\enk\\\\\o\\\\\000\0\eng\d
000045103 0247_ $$a10.1093/jiplp/jpab150$$2doi
000045103 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000045103 041__ $$aeng
000045103 24500 $$aThe IP waiver and COVID-19:$$breasons for unwavering support.
000045103 264_1 $$a[Oxford, England] :$$bOxford University Press (OUP),$$c2021
000045103 300__ $$a1 online resource (pages 1347-1359)
000045103 337__ $$acomputer$$2rdamedia
000045103 4901_ $$aJournal Of Intellectual Property Law & Practice,$$x1747-1540 ;$$v16, 12, 2021
000045103 542__ $$fhttps://academic.oup.com/jiplp/article/16/12/1347/6459539
000045103 588__ $$aCrossref
000045103 590__ $$aPublished online: 11-Dec-21
000045103 650_0 $$aIntellectual property.
000045103 650_0 $$aCovid-19.
000045103 650_0 $$aScience and Technology$$xVaccine Development.
000045103 7001_ $$aFoss-Solbrekk, Katarina,$$eauthor.
000045103 7731_ $$tJournal of Intellectual Property Law & Practice$$wjiplp
000045103 830_0 $$aJournal Of Intellectual Property Law & Practice ;$$v16, 12, 2021.
000045103 85641 $$uhttps://doi.org/10.1093/jiplp/jpab150$$yOnline version
000045103 904__ $$aJournal article
000045103 980__ $$aJIPLP